Research Progress of Perioperative Immunotherapy for Locally Advanced Gastric Cancer
Gastric cancer is one of the major malignant tumors in China,and radical surgery is the only chance for patients to be cured,however,only 50％～60％of patients are suitable for radical surgery,for the patients with locally advanced and advanced stages often lose the chance of surgery.The results of the MAGIC and ACCORD07/FFCD9703 studies confirmed fluorouracil-based combination chemotherapy regimens as the standard of perioperative treatment for locally advanced gastric cancer;however,the 5-year overall survival of gastric cancer patients is still relatively low.Immunotherapy,including immune checkpoint inhibitors,tumor vaccines and cellular therapy,has shown significant efficacy in the first-line treatment of advanced gastric cancer,and also demonstrated safety and efficacy in the perioperative treatment of patients with locally advanced gastric cancer.This paper reviews the research progress of immunotherapy in the perioperative treatment of locally advanced gastric cancer.
NETL
NSTL
万方数据
